Roflumilast Ocular Topical Administration for Anterior and Vitreous Chamber Diseases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for anterior and vitreous chamber ocular diseases, such as uveitis, face challenges in delivering effective pharmaceuticals to these immune-rich but difficult-to-reach areas of the eye, often requiring frequent dosing and resulting in side effects.
Innovation Solution
The use of ophthalmic pharmaceutical compositions of roflumilast, administered topically to the ocular surface at higher concentrations and frequencies, provides therapeutic coverage of PDE4A, B, and D in the anterior and vitreous chambers, downregulating Th17 and Th1 immune targets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional corticosteroid treatments are used for anterior and vitreous chamber ocular diseases, then therapeutic efficacy is achieved, but dosing frequency must be high and side effects increase
Solution Approach 1:
The patent changes the chemical parameter by substituting corticosteroids with roflumilast, a PDE4 inhibitor, which has different pharmacological properties. This parameter change allows for effective treatment of anterior and vitreous chamber ocular diseases with reduced side effects and lower dosing frequency compared to traditional corticosteroid treatments
2Reliability
If traditional corticosteroid treatments are used for anterior and vitreous chamber ocular diseases, then therapeutic efficacy is achieved, but dosing frequency must be high
Solution Approach 1:
The patent changes the pharmacological parameter by using roflumilast instead of corticosteroids, which results in sustained therapeutic efficacy with reduced dosing frequency. The PDE4 inhibition mechanism provides prolonged anti-inflammatory effects, reducing the time loss associated with frequent dosing
3Ease of operation
If pharmaceutical agents are delivered topically to the ocular surface, then administration is simplified, but achieving effective therapeutic levels in anterior and vitreous chambers is difficult
Solution Approach 1:
The patent changes the pharmacokinetic parameter by utilizing roflumilast's ability to achieve sustained therapeutic levels in the aqueous humor and vitreous chamber following topical ocular surface administration. This parameter change maintains administration simplicity while ensuring reliable therapeutic coverage of anterior and vitreous chamber diseases
4Reliability
If higher concentrations of roflumilast are administered topically, then therapeutic coverage of PDE4A, B, and D is achieved, but formulation challenges increase
Solution Approach 1:
The patent changes the concentration parameter of roflumilast in the ophthalmic formulation to achieve adequate PDE4A, B, and D inhibition in the anterior and vitreous chambers. This parameter change provides reliable therapeutic coverage while the formulation is designed to maintain stability and tolerability despite the higher concentration requirements
Data Source
AI summary
Methods of treating anterior or vitreous chamber ocular diseases by administering ophthalmic pharmaceutical compositions of roflumilast topically to the ocular surface of the eye of a patient. The methods involving topical administration of ophthalmic pharmaceutical compositions of roflumilast to the ocular surface of a patient three or four times a day at more frequent and higher concentration, which can provide significant therapeutic activity to the anterior and vitreous chamber compartments of the eye using dosing regimens involving higher concentrations and less frequent administration than other treatment regimens.